Medicines for Malaria Venture (MMV)
MMV, a not-for-profit public-private partnership, was established as a foundation in Switzerland in 1999.
Our mission
To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs.
Our vision
A world in which these innovative medicines will cure and protect the vulnerable and under-served populations at risk of malaria, and help to ultimately eradicate this terrible disease.
Gates Foundation & MMV at ASTMH 2025 (7/7)
Gates Foundation & MMV at ASTMH 2025 (6/7)
Gates Foundation & MMV at ASTMH 2025 (5/7)
Фонд Гейтса и MMV на выставке ASTMH 2025 (4/7)
Gates Foundation & MMV at ASTMH 2025 (3/7)
Gates Foundation & MMV at ASTMH 2025 (2/7)
Фонд Гейтса и MMV на выставке ASTMH 2025 (1/7)
Cómo utilizar la prueba STANDARD™ G6PD
Science of malaria medicine symposium: opening remarks
Science of malaria medicine symposium: session 1
Science of malaria medicine symposium: session 2
Science of malaria medicine symposium: session 3
Science of malaria medicine symposium: session 4
Science of malaria medicine symposium: closing remarks
MMV's values: the energy that moves us
Ending the echo: the Partnership for Vivax Elimination
Perú incorpora la tafenoquina de dosis única con prueba de G6PD en su Norma Técnica de Salud
Peru adopts single-dose tafenoquine with G6PD testing into national guidelines
About Medicines for Malaria Venture
Poniendo fin al eco: la Alianza para la Eliminación de Vivax
MMV-supported medicines
Single-dose relapse prevention treatment for vivax malaria
ABC- The first malaria treatment for babies
When the hospital is too far: saving lives from severe malaria in hard-to-reach areas (cutdown)
When the hospital is too far: saving lives from severe malaria in hard-to-reach areas
Advancing research and innovation to boost maternal health
Nueva formulación de artesunato inyectable a base de arginina para la malaria grave
Nouvelle formulation d'artésunate injectable à base d'arginine pour le paludisme grave